https://ift.tt/3a9aIOL
3D Printed, Vascularized Lung Models Push 3D Systems into Bioprinting https://ift.tt/3ovPeRz 3D Systems (NYSE:DDD) has announced that it is diving further into the bioprinting space, upon significant progress made by its partner United Therapeutics Corporation (NASDAQ:UTHR) and its subsidiary Lung Biotechnology PBC. Together, the companies have developed a method for quickly fabricating hydrogel scaffolds that are then perfused with living cells. The technology has shown such promising results for tissue engineering applications that 3D Systems has decided to invest much more into bioprinting. The partnership between 3D Systems and United Therapeutics began in 2017 and, after three years of work, they were able to create a method for rapidly 3D printing full-size, vascularized lung scaffolds with micron-level detail. This resulted in 3D Systems’ development of an entire portfolio of bioprinters and biomaterials for, in the company’s words, “lung manufacturing.” 3D Systems calls the process “Print to Perfusion” and it involves using Figure 4 systems to 3D print “large, vascularized, highly detailed hydrogel scaffolds at rapid speeds” that are then permeated with living cells. The company’s Figure 4 system will be expanded to better address bioprinting and regenerative medicine. The company’s continuous digital light processing platform is a truly fast method for making organ scaffolds, as Figure 4 is able to 3D print complete objects in just minutes.
3D Systems suggests that the technology will not only apply to lungs, but other tissues, as well. This will see it pour more resources into programs associated with different applications in the space, as well as bringing additional experts onto its bioprinting team. It will also deepen its partnerships with Israel’s CollPlant Biotechnologies (NASDAQ:CLGN) and Belgium’s Antleron. CollPlant’s proprietary recombinant human collagen (rhCollagen) BioInk was crucial in the lung printing project with United Therapeutics and its organ manufacturing and transplant subsidiary, Lung Biotechnology PBC. The company is already heavily involved in the bioprinting space since at least 2016, most recently working with United Therapeutics on 3D printing kidneys. With 3D Systems handling the 3D printers and CollPlant the BioInks, the partners will be able to develop tissue and scaffold bioprinting processes for third parties. In 2019, 3D Systems also began to collaborate with Antleron, which combines 3D printing, bioreactors and artificial intelligence to transform cells into biotherapeutic solutions. The exact nature of their partnership is a bit clouded in marketing-speak, but involves the use of 3D Systems’ ProJet MJP 2500 and Figure 4 3D printers, as well as its materials and software. The ultimate goal is to “make 3D printing an integrated part of modular and digital factory-of-the-future solutions to enable sustainable and personalized manufacturing of cell & gene therapies, vaccines, tissues, and organs.”
3D Systems has an established reputation in the medical field, which Viyamesh Joshi highlighted during his tenure as the firm’s CEO. This is embodied in its Colorado-based healthcare facility, which not only 3D prints dental and medical devices but also develops its virtual surgical planning technologies. With a robust bioprinting portfolio, the company will be able to move even further into the digital medicine space. Bioprinted organs and tissues will allow for testing and drug development that don’t rely on animal test subjects. Given the market turnaround that has already occurred under Graves, it’s hard not to think that this news won’t also cause a stir for 3D Systems. As Vice President of Research for SmarTech Analysis Scott Dunham recently noted, this time in the 3D printing industry feels akin to the excitement that percolated circa 2014. Whereas desktop machines were driving most of the attention then, industrial 3D printing is doing so now. Bioprinting has made such progress since then that we have an entire map dedicated to this subsegment. My hope is that, as good as this news may be for 3D Systems, it might actually mean 3D printed organs may be ready for transplant sooner rather than later. For full transparency, I own a very small number of shares of 3D Systems stock. Printing via 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing https://3dprint.com January 27, 2021 at 07:32AM
0 Comments
Leave a Reply. |
Categories
All
Archives
April 2023
|